Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yeonjy Lee
Institution:
Qurient (South Korea)
Observed institution:
Qurient (South Korea)
ORCID:
0009-0006-1142-2569
Observed ORCID:
0009-0006-1142-2569
OpenAlex ID:
A5108910962
Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2025
·
Chansik Kim
, Jinwoo Park
, et al.
·
Molecular Cancer Therapeutics
·
2
Figure S1 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
·
1
Abstract 3142: NN3201, a novel c-Kit targeting ADC, exhibits robust preclinical anti-tumor efficacy in SCLC and GIST models
2024
·
Chansik Kim
, Jin Gu Cho
, et al.
·
Cancer Research
·
1
Abstract A009: Preclinical safety and efficacy QP101: A novel HER2-targeting dual payload ADC combining topoisomerase I (TOP1) and cyclin dependent kinase 7 (CDK7) inhibitors
2026
·
Kiyean Nam
, Hwankyu Kang
, et al.
·
Clinical Cancer Research
Figure S9 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S8 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Table S2 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
Figure S2 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S5 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S3 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Data from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
Figure S6 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Table S1 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S10 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S4 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Figure S7 from Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
2026
·
Chansik Kim
, Jinwoo Park
, et al.
PDF
Show more works
View as search
Works count:
16
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type